Science: THE BREAST CANCER STORY
Sunday 09 November 1997
The story begins in 1991 when geneticists from Berkeley, California located a gene linked to familial breast cancer (BrCa1) on chromosome 17. This wasn't the only breast cancer gene as not all predisposed families had it. So, funded by the Cancer Research Campaign, Stratton and a team from the Institute of Cancer Research in London hunted for another gene. Believing their set of DNA samples would not be powerful enough to highlight a new gene, they agreed to share samples with European and US groups, including one from the University of Utah.
In 1994, Stratton then located a new gene, BrCa2, on chromosome 13 and was about to embark on the hard work of isolating it when the Utah University group isolated BrCa1 and decided to set up a company called Myriad Genetics to develop its commercial potential. "At this point we decided that we could not collaborate with Utah. One reason was that it is hard to look into the future and see what could happen if a company owned a gene as interesting as BrCa2. Also, we would be in collaboration with a commercial enterprise, but our main research base continued to be samples from patients, none of whom had been asked if we could give their sample to a commercial company."
So Stratton and co decided to go it alone and what was a collaboration became a competition. "We thought this was the end of our chances of being successful because Myriad Genetics was very experienced and heavily financed. But we did it and published in December 1995 with about three- quarters of the sequence. In March Myriad published, confirming our findings, and completing the remaining quarter of the sequence."
Then came the crux. To develop a useful diagnostic test for familial breast cancer, both genes would need to be involved. Myriad had already moved to take out a patent on BrCa1 and was proving an aggressive player.
"If we didn't take out a patent on BrCa2, they could have a monopoly on that too and have the power to prevent anyone else developing a test. We are wary of gene patents, but decided it was the only safe thing to do to retain any control of the use of our findings."
Defending a patent is expensive and Stratton's funders, the Cancer Research Campaign didn't feel they could use charitable money to this end. So this year the patent was sold to a US biotech company, Oncomed, in a contract festooned with protective provisos. Chief among them - any test developed with BrCa2 must only be made available to people referred by a clinician expert in the management of familial breast cancer and who gives full pre- and post-test counselling.
There must also be absolutely no lay advertising: "We don't want any drumming up of business to increase people's concern."
In addition, Oncomed must sub-license the patent to all other commercial organ- isations that want to develop a test or therapy, providing they agree to be bound by the ethical code. Finally, no not-for-profit organ-isation, including the NHS, can be charged for using BrCa2 in any way. "We did the work in the public sector, financed by charitable donations in state institutions. We did not want to find them paying again." There's little doubt Oncomed will profit from the licence, but so too will CRC. For the record, says Stratton, he has waived all personal royalties.
How effective this ethical approach is remains to be seen. But Stratton believes trying to return science to an unpatentable Garden of Eden is a non-starter. "In the Eighties when few genes had been patented, it might have been possible to stop it, and there would still have been the incentive to produce diag- nostics and therapeutics because genes are the primary resource of modern medicine. With some genes patented, companies are only going to work on those they can get the patent on because they believe they need that degree of security. If we stop now, new unpatented genes will simply be ignored.
"From here on in, any scientists working with anything remotely developable will have to consider the implications of patents."
Review: Imaginative storytelling returns with vigourfilm
Bannatyne leaves Dragon's DenTV
Arts & Ents blogs
- 1 Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
- 2 Loom bands: Bids for dress made from colourful rubber reach almost £154,000 on eBay
- 3 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
- 4 Why I'm on the brink of burning my Israeli passport
- 5 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
War is war: Why I stand with Israel